培美曲塞联合卡铂或顺铂对复发性卵巢上皮癌患者的疗效及安全性分析
|
摘要
目的探讨培美曲塞联合卡铂与顺铂对复发性卵巢上皮癌患者的疗效及安全性。方法回顾性选择濮阳市油田总医院2012年1月—2015年12月收治的53例复发性卵巢上皮癌患者,根据化疗方法的不同分为A组及B组,A组26例,采用培美曲塞联合顺铂治疗,B组27例,采用培美曲塞联合卡铂治疗,对比两组的临床疗效、无进展生存期及不良反应。结果A组治疗有效率为34.6%,B组为40.7%,两组有效率对比无统计学意义。A组平均无进展生存期为(9.1±1.9)个月,B组为(9.7±1.8)个月,组间对比无统计学意义。A、B两组的Ⅲ～Ⅳ血液学毒性、乏力、Ⅲ～Ⅳ消化道反应对比无统计学意义;而B组的Ⅲ～Ⅳ周围神经病变、Ⅲ～Ⅳ脱发、发热发生率明显低于A组,差异有统计学意义(P<0.05)。结论培美曲塞联合卡铂与培美曲塞联合顺铂对复发性卵巢上皮癌的效果相当,但培美曲塞联合卡铂的安全性较高。
Objective To investigate the efficacy and safety of pemetrexed combined with carboplatin and cisplatin in patients with recurrent ovarian epithelial cancer. Methods 53 cases with recurrent ovarian epithelial cancer from Jan. 2012 to Dec. 2015 in our hospital were retrospective selection, who were divided into the group A (26 cases) and group B (27 cases), group A were given pemetrexed combination with cisplatin, group B were given pemetrexed combination with carboplatin, the clinical efficacy,progression-free survival and adverse events of two groups were compared.Results The clinical efficacy of group A was 34.6%, the group B was 40.7%, which in two groups had no significant difference. The progression-free survival of group A was (9.1 ± 1.9)months, which in the group B was (9.7 ± 1.8) months. The Ⅲ—Ⅳ hematological toxicity, weak, Ⅲ—Ⅳ digestive tract reaction of two groups had no significant difference. The Ⅲ — Ⅳ peripheral neuropathy, Ⅲ — Ⅳ hair loss, fever of group B were lower than group A (P < 0.05). Conclusion Pemetrexed combined with carboplatin and pemetrexed combined with cisplatin was equally effective in recurrent ovarian epithelial cancer, while pemetrexed combined with carboplatin was safer.
Objective To investigate the efficacy and safety of pemetrexed combined with carboplatin and cisplatin in patients with recurrent ovarian epithelial cancer. Methods 53 cases with recurrent ovarian epithelial cancer from Jan. 2012 to Dec. 2015 in our hospital were retrospective selection, who were divided into the group A (26 cases) and group B (27 cases), group A were given pemetrexed combination with cisplatin, group B were given pemetrexed combination with carboplatin, the clinical efficacy,progression-free survival and adverse events of two groups were compared.Results The clinical efficacy of group A was 34.6%, the group B was 40.7%, which in two groups had no significant difference. The progression-free survival of group A was (9.1 ± 1.9)months, which in the group B was (9.7 ± 1.8) months. The Ⅲ—Ⅳ hematological toxicity, weak, Ⅲ—Ⅳ digestive tract reaction of two groups had no significant difference. The Ⅲ — Ⅳ peripheral neuropathy, Ⅲ — Ⅳ hair loss, fever of group B were lower than group A (P < 0.05). Conclusion Pemetrexed combined with carboplatin and pemetrexed combined with cisplatin was equally effective in recurrent ovarian epithelial cancer, while pemetrexed combined with carboplatin was safer.
引文
[1]张迎旭,贾秀改,田永,等.卵巢上皮癌患者无进展生存期差异性研究[J].热带医学杂志,2017,17(7):956-958,965.
[2]黄志有,马必东,黄兆明.复发性卵巢上皮癌女性患者无瘤生存状况及其影响因素分析[J].中国妇幼健康研究,2017,28(7):788-789,896.
[3]别俊,何朗,张玉红,等.热疗联合吉西他滨治疗铂类耐药型卵巢上皮癌的疗效观察[J].中国肿瘤临床与康复,2017,24(8):975-977.
[4]裴颖.肿瘤细胞减灭术联合化疗治疗卵巢上皮癌的效果[J].中国医药导报,2016,13(2):65-68.
[5]胡远强,张永波,王华,等.多西他赛联合卡铂与紫杉醇联合顺铂治疗晚期卵巢癌的疗效和安全性比较[J].中国药房,2016,27(24):3353-3355,3356.
[6]纵艳艳,刘江英.新辅助化疗联合腹腔镜下中间型肿瘤细胞减灭术治疗ⅢC期卵巢上皮性癌的临床研究[J].中华全科医学,2017,15(6):1091-1092.
[7]李雷,向阳.铂类药物超敏反应的研究进展[J].中华妇产科杂志,2016,51(11):877-880.
[8]付清茹,齐红岩,荣安娜.晚期卵巢上皮癌新辅助化疗的研究进展[J].医学综述,2017,23(5):891-895.
[9]白枫,赫丽杰,李辉,等.DC-CIK细胞免疫疗法在卵巢上皮癌治疗中的疗效分析[J].广西医科大学学报,2016,33(5):860-862.
[10]廖胜斌,计峰,陈昌贤,等.血清CA125预测卵巢上皮癌治疗后复发的Meta分析[J].现代妇产科进展,2017,26(2):86-90.
[11]林紫瑜.新辅助化疗后腹式中间型肿瘤细胞减灭术治疗卵巢上皮癌ⅢC期的临床研究[J].中国综合临床,2017,33(1):57-59.
[12]楚晨龙,周文龙,赵晨晖,等.培美曲塞联合顺铂治疗晚期尿路上皮癌的疗效与安全性研究[J].现代生物医学进展,2016,16(15):2864-2867.
[13]吴晓阜,田晓云,徐欣昌,等.培美曲塞联合顺铂治疗晚期复发性非小细胞肺癌的临床研究[J].淮海医药,2016,34(2):137-139,141.
[14]程鑫,邝文明,闫海山.培美曲塞联合顺铂或卡铂治疗复发或转移性非小细胞肺癌的临床研究[J].药品评价,2017,14(14):35-38.
[15]陈红,周晓红,陆国权,等.培美曲塞注射剂联合顺铂注射剂治疗复发性肺腺癌的临床研究[J].中国临床药理学杂志,2017,33(12):1079-1081.
[16]李雷,吴鸣,杨佳欣,等.卵巢上皮性癌和子宫颈癌患者铂类药物超敏反应的临床分析[J].中华妇产科杂志,2016,51(11):825-831.
[2]黄志有,马必东,黄兆明.复发性卵巢上皮癌女性患者无瘤生存状况及其影响因素分析[J].中国妇幼健康研究,2017,28(7):788-789,896.
[3]别俊,何朗,张玉红,等.热疗联合吉西他滨治疗铂类耐药型卵巢上皮癌的疗效观察[J].中国肿瘤临床与康复,2017,24(8):975-977.
[4]裴颖.肿瘤细胞减灭术联合化疗治疗卵巢上皮癌的效果[J].中国医药导报,2016,13(2):65-68.
[5]胡远强,张永波,王华,等.多西他赛联合卡铂与紫杉醇联合顺铂治疗晚期卵巢癌的疗效和安全性比较[J].中国药房,2016,27(24):3353-3355,3356.
[6]纵艳艳,刘江英.新辅助化疗联合腹腔镜下中间型肿瘤细胞减灭术治疗ⅢC期卵巢上皮性癌的临床研究[J].中华全科医学,2017,15(6):1091-1092.
[7]李雷,向阳.铂类药物超敏反应的研究进展[J].中华妇产科杂志,2016,51(11):877-880.
[8]付清茹,齐红岩,荣安娜.晚期卵巢上皮癌新辅助化疗的研究进展[J].医学综述,2017,23(5):891-895.
[9]白枫,赫丽杰,李辉,等.DC-CIK细胞免疫疗法在卵巢上皮癌治疗中的疗效分析[J].广西医科大学学报,2016,33(5):860-862.
[10]廖胜斌,计峰,陈昌贤,等.血清CA125预测卵巢上皮癌治疗后复发的Meta分析[J].现代妇产科进展,2017,26(2):86-90.
[11]林紫瑜.新辅助化疗后腹式中间型肿瘤细胞减灭术治疗卵巢上皮癌ⅢC期的临床研究[J].中国综合临床,2017,33(1):57-59.
[12]楚晨龙,周文龙,赵晨晖,等.培美曲塞联合顺铂治疗晚期尿路上皮癌的疗效与安全性研究[J].现代生物医学进展,2016,16(15):2864-2867.
[13]吴晓阜,田晓云,徐欣昌,等.培美曲塞联合顺铂治疗晚期复发性非小细胞肺癌的临床研究[J].淮海医药,2016,34(2):137-139,141.
[14]程鑫,邝文明,闫海山.培美曲塞联合顺铂或卡铂治疗复发或转移性非小细胞肺癌的临床研究[J].药品评价,2017,14(14):35-38.
[15]陈红,周晓红,陆国权,等.培美曲塞注射剂联合顺铂注射剂治疗复发性肺腺癌的临床研究[J].中国临床药理学杂志,2017,33(12):1079-1081.
[16]李雷,吴鸣,杨佳欣,等.卵巢上皮性癌和子宫颈癌患者铂类药物超敏反应的临床分析[J].中华妇产科杂志,2016,51(11):825-831.